NEW YORK – Drawing on its longstanding partnership with Becton Dickinson, Babson Diagnostics is aiming to further expand use of its US Food and Drug Administration-cleared blood collection system ...
Barclays raised the firm’s price target on Becton Dickinson (BDX) to $279 from $278 and keeps an Overweight rating on the shares. The firm says ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback